Humalog
insulin lispro
Table of contents
Overview
Humalog is a range of insulin medicines used to treat patients who have diabetes and need insulin to keep their blood glucose (sugar) level controlled, including patients whose diabetes has just been diagnosed.
Humalog medicines contain the active substance insulin lispro on its own or combined with protamine to make it longer acting:
- Humalog (100 units/ml): standard-strength insulin lispro (fast-acting);
- Humalog (200 units/ml): high-strength insulin lispro (fast-acting);
- Humalog Mix25 (100 units/ml): 25% insulin lispro (fast-acting) and 75% insulin lispro protamine (longer-acting);
- Humalog Mix50 (100 units/ml): 50% insulin lispro (fast-acting) and 50% insulin lispro protamine (longer-acting).
Authorisation details
Product details | |
---|---|
Name |
Humalog
|
Agency product number |
EMEA/H/C/000088
|
Active substance |
insulin lispro
|
International non-proprietary name (INN) or common name |
insulin lispro
|
Therapeutic area (MeSH) |
Diabetes Mellitus
|
Anatomical therapeutic chemical (ATC) code |
|
Publication details | |
---|---|
Marketing-authorisation holder |
Eli Lilly Nederland B.V.
|
Revision |
34
|
Date of issue of marketing authorisation valid throughout the European Union |
30/04/1996
|
Contact address |
Papendorpseweg 83 |
Product information
07/09/2021 Humalog - EMEA/H/C/000088 - N/0192
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Drugs used in diabetes
Therapeutic indication
For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus.